Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. - Wikidata - awgldk - TriplyDB

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

http://www.wikidata.org/entity/Q36926105

about

Metabolic complications of androgen deprivation therapy for prostate cancer Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?Cardiovascular effects of hormone therapy for prostate cancer Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy Management of patients with biochemical recurrence after local therapy for prostate cancer Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Management of complications of prostate cancer treatment.Cardiac and cognitive effects of androgen deprivation therapy: are they real?HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness.Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database Cardiovascular risk during hormonal treatment in patients with prostate cancer.Management of complications of androgen deprivation therapy in the older man.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks Metabolic effects of androgen deprivation therapy Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer Androgen deprivation therapy toxicity and management for men receiving radiation therapy Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).Long-term Toxicity of Cancer Treatment in Older Patients Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.Emerging cardiometabolic complications of androgen deprivation therapy.Safety and tolerability of intermittent androgen deprivation therapy: a literature review.Triptorelin in the management of prostate cancer.Testosterone and obesity.Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.Metabolic syndrome in prostate cancer: impact on risk and outcomes

P2860

Q24616159-EA3D5338-9A33-4F37-8D33-C8C128795AB1 Q26738281-9346B7CE-B987-4288-8AB0-6E7ED768BC00 Q26749088-B76C1981-5873-4745-8B05-9E84D9AFBBAB Q26801112-6938B00F-A805-42E0-8742-DBB9E4470B5B Q26801188-61E90EBD-7A84-4F96-855D-AE80FCBB56E9 Q26849220-B7F61E4A-587B-4A5C-80FC-A8DBEE975BB5 Q26864943-EEE05AAD-A5B0-4E9F-92D1-CE337134DAF2 Q33900049-1DD078D4-FF79-44CF-BBB6-1C5D197CFB6A Q33977523-5B94BF72-CFF2-4E76-9A96-8A7025F54950 Q33978360-1D28E944-7E05-4D26-BD83-F871DB8F92FE Q34111628-9B3C16C8-2882-47DB-8B06-8E3E20A39028 Q34155075-7D9B3E59-97EC-479B-8FC1-75905ACA26D7 Q34411758-0F41E2BE-AB4F-4C17-81CB-DDE0F5C71053 Q34505196-DBCAB4E2-FBCA-4FFB-A5A3-9E10F16DCF86 Q34516434-29B88CBE-ADE1-4733-9862-A5659BA141A3 Q34617897-1F4D4072-BD90-40FF-8F6A-ED29593AF48E Q34617924-63A94636-33BC-488C-8B76-25E28FF69A3B Q34663266-6351EB19-66AB-4A1F-8966-A908071AA9CD Q34721165-AD6E53D2-3AEB-4B4D-995E-7A658E9CE894 Q34782101-46E82060-A4C2-460D-A088-7C2FC2FCBF7F Q34960686-3625DFA0-162A-43E4-A354-45F00D11992A Q34962416-C9EF3EF0-9985-4C08-BE77-01ABC87D13D8 Q35689824-218468E2-B9D6-4F93-8867-30213B0787D0 Q35754723-E0B4CE0F-650F-4566-A440-633137D4DCDA Q35951635-05E36856-0E22-41BB-8540-B4202687AB78 Q36530136-7A94E80F-2105-4890-B179-58283B232626 Q36751550-9DF33513-C00B-4D02-8F0F-B1FA804A6B0D Q36821673-D4354EE3-1C57-437A-89D8-07C829E01274 Q36866314-C7C89B8E-F8E9-4EE3-B71F-D5025981C52B Q36898849-C9A4ED74-BD88-4D4B-BDB5-375D14A13987 Q37085223-D5AE7F4E-7AF0-4608-9054-A2FC29BA21CD Q37331782-0121F9EA-2533-483F-BCED-01748C618DE8 Q37390104-6F290BA1-F2E2-434D-B74A-DA87550688D2 Q37431937-20FA9331-D044-41DD-B10F-3D7209B8272F Q37690775-4DE6DBC2-5ED6-43D2-97CE-3E9237189921 Q37995670-5FA9CE5C-D8FD-4C81-93A2-31E91A4A9A86 Q38068495-6231B4F7-B63D-4CEA-BC32-72AA72702FD5 Q38485746-75BFDBB0-4618-40E8-9F38-C3201B477CE7 Q38707724-6B49EF52-4F03-444A-9253-649D547AB4D0 Q38805127-9629D846-04C8-4508-95E9-C7BA73909685

P2860

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

http://www.wikidata.org/entity/Q36926105

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Metabolic changes during gonad ...... he classic metabolic syndrome.

@en

type

label

Metabolic changes during gonad ...... he classic metabolic syndrome.

@en

prefLabel

Metabolic changes during gonad ...... he classic metabolic syndrome.

@en

P1433

Q36926105-83AB674D-EA00-458E-99D9-015E84EF610A

P1476

Q36926105-AB4CAD2D-C61A-4853-A070-6E3DBA1466BB

P2093

Q36926105-0CCF8DD0-A367-44CF-BCDD-5CBE21258820

Q36926105-327DF601-900A-4B92-A8C2-5DC19F9E2CEE

Q36926105-36018B4E-581C-4D7E-A379-D482195A311A

Q36926105-42126077-DCD8-4AE0-9012-3B0BAD93BDC2

Q36926105-605C6E0D-C2AF-4817-BEDA-8BE950480A25

Q36926105-62C398E9-EE61-4031-AA96-1C030B9119D3

Q36926105-CBB53879-D5DA-43F7-AAB2-931B19997CF6

P2860

Q36926105-016926DA-A259-498B-9723-27C3CAE21379

Q36926105-183C25C6-1310-45ED-9FF4-B332E0519604

Q36926105-2E4C6465-1106-423B-9B7B-6BB072414A83

Q36926105-31883871-4291-41BF-81AF-545D9C51E7B5

Q36926105-38BBCA4A-6B21-4BC0-8ABB-0B8DFBCA299A

Q36926105-404CC842-FEB6-4673-B507-A57B628DD8A9

Q36926105-4153EA62-75FC-4614-A26E-F64D4981900C

Q36926105-6614D60D-8765-4D3C-B6A3-F8975D07F666

Q36926105-6C583954-7BE3-4A67-83A5-A6BD5AAE9C9F

Q36926105-6FA286F9-899C-4BAA-A6F6-F13BB0460CE0

P304

Q36926105-BE041650-374D-445C-A5B1-31CFC7520933

P31

Q36926105-F9F77E33-EB49-43D3-9EE7-A3B80E718A11

P356

Q36926105-E1C28A88-442E-47AE-B3E3-7CEAE6BAE58D

P407

Q36926105-C6A10995-8CED-4ED2-9E9C-3E30F43A6D17

P433

Q36926105-C9D8115D-7B29-476F-BC41-6EE231473F10

P478

Q36926105-E248E496-57E7-4C0D-BF8E-48207516E465

P577

Q36926105-CBDBB594-1CC9-41DD-9684-C67DB50177A4

P5875

Q36926105-079C4F45-216E-46A3-9344-F6C24E5F527C

P698

Q36926105-692AD3A3-EA53-4D62-8B01-ECDD5A61D69D

P921

Q36926105-5BCCDD4F-445D-490B-9E9B-E6603815636A

P932

Q36926105-25C22923-5A72-474A-B5E0-6F576D7E5619

P356

P1433

P1476

Metabolic changes during gonad ...... he classic metabolic syndrome.

@en

P2093

Anthony L Zietman

http://www.w3.org/2001/XMLSchema#string

Francis McGovern

http://www.w3.org/2001/XMLSchema#string

Hang Lee

http://www.w3.org/2001/XMLSchema#string

Joel S Finkelstein

http://www.w3.org/2001/XMLSchema#string

Mary Anne Fallon

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

Melissa Goode

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Banting lecture 1988. Role of insulin resistance in human disease

Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

The insulin resistance syndrome: definition and dietary approaches to treatment.

The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.

Metabolic syndrome: a solution in search of a problem.

Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study

P304

2188-2194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23440

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5504760

http://www.w3.org/2001/XMLSchema#string

P698

18348297

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome

P932

2562782

http://www.w3.org/2001/XMLSchema#string